Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Alder Biopharmaceuticals

- PMLiVE

Italy investigates Novartis vaccine after death toll reaches 13

Firms insist on the Fluad's safety, with 65 million doses given in the last 17 years

- PMLiVE

Novartis’ Gilenya fails in difficult-to-treat form of MS

Drug no better than placebo as a treatment for primary progressive multiple sclerosis

- PMLiVE

Novartis’ heart failure drug on EMA’s fast track

Candidate is the first cardiovascular drug to get accelerated review in the EU

- PMLiVE

NICE overturns negative Glivec guidance

Recommends drug for reimbursement in GIST four years after rejection

- PMLiVE

Teva board elects Yitzhak Peterburg as chairman

He succeeds Phillip Frost

- PMLiVE

Novartis brings creative malaria campaign to Pinterest

Invites users to create their own mosquito-killing story

- PMLiVE

Amgen/AZ confirm brodalumab psoriasis filing in 2015

Drug demonstrates greater effectiveness than J&J’s Stelara

Novartis day

FDA needs more time to review Novartis’ cancer drug

Panobinostat is being investigated for use in multiple myeloma

- PMLiVE

Novartis partners with NHS on eye service

Launches community programme in Bristol

- PMLiVE

Deaths cause Amgen to drop stomach cancer drug

Increase in patient mortality in patients taking rilotumumab during trial

EU flag

Orphan drugs in latest CHMP recommendations

EMA advisers back new products from Genzyme, Boehringer and others

- PMLiVE

Novartis gets EU nod for rare disease drug Signifor

Long-acting formulation of drug approved for growth disorder acromegaly

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links